DXR — Daxor Corporation
NASDAQ · Healthcare · Medical Instruments & Supplies
$10.90
+$0.82 (+8.14%)
Daxor Corporation (DXR) is a medical instruments & supplies company listed on NASDAQ. It is led by Michael Richard Feldschuh, based in 109 Meco Lane, Oak Ridge, TN, United States, 37830. Daxor Corporation engages in medical instrumentation and biotechnology operations. It develops the BVA-100 Blood Volume Analyzer, an instrument that measures human blood volume, in conjunction with Volumex, a single-use radiopharmaceutical diagnostic injection and collection kit. The company was formerly known as Idant Corporation and changed its name to Daxor Corporation in May 1973. Daxor Corporation was incorporated in 1971 and is headquartered in Oak Ridge, Tennessee. Daxor Corporation operates as a subsidiary of Estate Of Joseph Feldschuh.
Latest reported DXR revenue for 2011-12-31 was $1.4M. Net income was -$7.2M. Revenue was up 324.3% from 2011-09-30 to 2011-12-31. DXR currently screens at market cap $61.9M and trailing P/E 6.5.
Use this DXR page for company research — sector, financials, and the latest filing takeaway — not a live tape. The session quote (last, range, volume) lives on the DXR quote page. Cached 10-K, 10-Q, 8-K, and Form 4 exhibits are on the DXR SEC filings page. Lician reads the product cache first so this HTML stays unique to Daxor Corporation even when a live quote feed is slow.
About Daxor Corporation
Daxor Corporation engages in medical instrumentation and biotechnology operations. It develops the BVA-100 Blood Volume Analyzer, an instrument that measures human blood volume, in conjunction with Volumex, a single-use radiopharmaceutical diagnostic injection and collection kit. The company was formerly known as Idant Corporation and changed its name to Daxor Corporation in May 1973. Daxor Corporation was incorporated in 1971 and is headquartered in Oak Ridge, Tennessee. Daxor Corporation operates as a subsidiary of Estate Of Joseph Feldschuh.
DXR Key Statistics
Market Cap
$61.89M
Previous Close
$10.00
Day Range
$10.00 – $10.00
P/E Ratio
6.46
EPS
$0.00
Revenue
$1.45M
Net Income
-$7.19M
Gross Profit
$0.00
Free Cash Flow
$0.00
Revenue Growth
-8.4%
Profit Margin
-496.8%
DXR Financials
Annual income statement in USD. Latest reported periods first.
| Line | FY2011 | FY2010 |
|---|---|---|
| Revenue | $1.45M | $1.58M |
| Cost of Revenue | $0.00 | $0.00 |
| Gross Profit | $0.00 | $0.00 |
| Operating Income | $0.00 | $0.00 |
| Net Income | -$7.19M | $4.97M |
| EPS (Diluted) | $0.00 | $0.00 |
Total Assets
$85.72M
Total Debt
$0.00
Shareholders' Equity
$0.00
Cash & Equivalents
$59.63K
Operating Cash Flow
-$6.51M
Free Cash Flow
$0.00
Daxor Corporation Company Information
- Chairman, President & CEO
- Michael Richard Feldschuh
- Headquarters
- 109 Meco Lane, Oak Ridge, TN, United States, 37830
- Website
- www.daxor.com
- Phone
- 865-425-0555
- IPO / Founded
- 1992-03-17
- Sector
- Healthcare
- Industry
- Medical Instruments & Supplies